Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label attachment file name title
tabling member	label

Search

1017445

registered interest
date	30/11/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Zoledronic Acid
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, if he will take steps to ensure that there is equality geographically in the availability of Zoledronic acid for breast cancer treatment.
tabling member constituency	West Lancashire
tabling member printed	Rosie Cooper
uin	197655
answer	answer is ministerial correction date of answer 05/12/2018 answer text <p>Decisions on the routine availability of medicines, such as Zoledronic acid, are made locally by clinical commissioning groups (CCGs). CCGs make funding decisions based on the needs of their population. Commissioning is about getting the best possible health outcomes for the local population and this involves assessing local needs to inform priorities and strategies.</p><p> </p><p>Under their terms of service, clinicians are allowed to prescribe any product which they consider to be a medicine necessary for the treatment of their patients under the National Health Service, subject to two provisos: firstly, that the product is not included in Schedules 1 or 2 to the NHS (General Medical Services Contracts)(Prescription of Drugs etc.) Regulations 2004 and secondly, that the clinician is prepared to justify any challenges to their prescribing by their local CCG.</p><p> </p><p>Decisions on whether to routinely fund medicines should be taken in the context of the CCGs available resources to ensure that care is fairly allocated to all patients and, where appropriate, measured against the CCGs other service development priorities.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 05/12/2018 16:47:52 answering member 4067 label Biography information for Steve Brine
tabling member	1538 label Biography information for Rosie Cooper

1015137

registered interest
date	26/11/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Zholia Alemi
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what forms of redress are available to (a) patients and (b) family members of patients who were treated or assessed by Zholia Alemi who was employed as an NHS psychiatrist despite without qualifications for the role; and what steps his Department plans to take to contact those patients to provide guidance on those forms of redress.
tabling member constituency	Barrow and Furness
tabling member printed	John Woodcock
uin	195560
answer	answer is ministerial correction date of answer 29/11/2018 answer text <p>Redress for actions of National Health Service bodies may be obtained by making a complaint to the provider or the commissioner of the NHS service. A clinical negligence claim against the NHS may also be made.</p><p> </p><p>Patients or family members who have a concern about contact with Zholia Alemi or the care received by her have been advised to contact the local NHS service where they were treated.</p> answering member constituency Wimbledon answering member printed Stephen Hammond question first answered 29/11/2018 14:06:33 answering member 1585 label Biography information for Stephen Hammond
tabling member	3917 label Biography information for Lord Walney

1015153

registered interest
date	26/11/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Zholia Alemi
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps he is taking to inform (a) patients and (b) family members of patients who were treated or assessed by Zholia Alemi that she was employed as an NHS psychiatrist without qualifications for the role.
tabling member constituency	Barrow and Furness
tabling member printed	John Woodcock
uin	195569
answer	answer is ministerial correction date of answer 29/11/2018 answer text <p>NHS England has advised that it has established an Incident Management Group (IMG) to identify and assess any clinical concerns relating to the practise of Zholia Alemi. The IMG aims to confirm Zholia Alemi’s employment history, to assess clinical decisions made by her and to consider whether individuals need to be contacted in due course.</p><p> </p><p>Patients or family members who have a concern about Zholia Alemi or the care received by her have been advised to contact the local NHS service where they were treated.</p> answering member constituency Wimbledon answering member printed Stephen Hammond question first answered 29/11/2018 14:08:16 answering member 1585 label Biography information for Stephen Hammond
tabling member	3917 label Biography information for Lord Walney

1017453

registered interest
date	30/11/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Zholia Alemi
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, further to WPQ 195560, by what method of communication patients or family members who have a concern about contact with Zholia Alemi or the care received by her have been advised to contact the local NHS service where they were treated.
tabling member constituency	Barrow and Furness
tabling member printed	John Woodcock
uin	197656
answer	answer is ministerial correction date of answer 05/12/2018 answer text <p>The General Medical Council (GMC) has provided on its website information for patients who are concerned about contact with Zholia Alemi. Patients and family members are advised to speak to the general practitioner surgery, hospital or clinic where they were treated. The GMC’s contact centre is available to people seeking further information.</p> answering member constituency Wimbledon answering member printed Stephen Hammond question first answered 05/12/2018 16:35:05 answering member 1585 label Biography information for Stephen Hammond
tabling member	3917 label Biography information for Lord Walney

1050260

registered interest
date	28/01/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Yorkshire Ambulance Service NHS Trust
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what proportion of calls were responded to within the target timeframe in the area covered by Yorkshire Ambulance Service NHS Trust in each of the categories measured (a) in total and (b) in each by District Council Area Level in each month of 2018.
tabling member constituency	Keighley
tabling member printed	John Grogan
uin	213223
answer	answer is ministerial correction date of answer 04/02/2019 answer text <p>NHS England’s Ambulance Quality Indicators set out Yorkshire Ambulance Service NHS Trust performance against each of the categories measured in each month of 2018. The data is attached.</p><p> </p><p>Data by District Council area is not collected centrally. Ambulance response times are published monthly by NHS England at ambulance trust level.</p><p> </p><p>Data can be found online at the following address:</p><p> </p><p><a href="https://www.england.nhs.uk/statistics/statistical-work-areas/ambulance-quality-indicators/" target="_blank">https://www.england.nhs.uk/statistics/statistical-work-areas/ambulance-quality-indicators/</a></p> answering member constituency Wimbledon answering member printed Stephen Hammond question first answered 04/02/2019 14:54:59 answering member 1585 label Biography information for Stephen Hammond attachment 1 file name PQ213223 - data table.xlsx.docx title PQ213223 attached data
tabling member	382 label Biography information for John Grogan

1054826

registered interest
date	04/02/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Yellow Fever: Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, if he will make representations to Sanofi Pasteur on undertaking new research into the risks of adverse events, including psychosis, from using the vaccine Stamaril.
tabling member constituency	Gravesham
tabling member printed	Adam Holloway
uin	216210
answer	answer is ministerial correction date of answer 12/02/2019 answer text <p>As with all vaccines and medicines, the Medicines and Healthcare products Regulatory Agency (MHRA) closely monitors the safety of Stamaril yellow fever vaccine. The MHRA takes advice from the Government's independent scientific advisory body, the Commission on Human Medicines, when evaluating the risks and benefits of medicines and vaccines.</p><p> </p><p>The Marketing Authorisation Holder for Stamaril, Sanofi Pasteur, has statutory obligations to continuously monitor the safety, and balance of benefits and risks, of the vaccine.</p><p> </p><p>The potential risks of Stamaril are described in the prescribing information, the Summary of Product Characteristics, and the information for vaccine recipients, the Patient Information Leaflet. A recognised, very rare risk of Stamaril vaccine is Yellow Fever Vaccine-Associated Neurotropic Disease, known as YEL-AND. Whilst the symptoms of YEL-AND can include confusion and acute focal neurological deficits (e.g. affecting motor co-ordination), this is not typically associated with psychosis or other long-term psychiatric disorders.</p><p> </p><p>Further to other recent reports of serious suspected adverse reactions in United Kingdom travellers, the MHRA is in the process of further reviewing the balance of benefits and risks of Yellow Fever vaccine, which will include an analysis of neuropsychiatric events.</p> answering member constituency Thurrock answering member printed Jackie Doyle-Price grouped question UIN 216211 216213 question first answered 12/02/2019 17:04:11 answering member 4065 label Biography information for Dame Jackie Doyle-Price
tabling member	1522 label Biography information for Adam Holloway

1054828

registered interest
date	04/02/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Yellow Fever: Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what representations he has made to Sanofi Pasteur on ensuring that new technology is developed to eliminate the risks of adverse events, including psychosis, from the use of the vaccine Stamaril.
tabling member constituency	Gravesham
tabling member printed	Adam Holloway
uin	216211
answer	answer is ministerial correction date of answer 12/02/2019 answer text <p>As with all vaccines and medicines, the Medicines and Healthcare products Regulatory Agency (MHRA) closely monitors the safety of Stamaril yellow fever vaccine. The MHRA takes advice from the Government's independent scientific advisory body, the Commission on Human Medicines, when evaluating the risks and benefits of medicines and vaccines.</p><p> </p><p>The Marketing Authorisation Holder for Stamaril, Sanofi Pasteur, has statutory obligations to continuously monitor the safety, and balance of benefits and risks, of the vaccine.</p><p> </p><p>The potential risks of Stamaril are described in the prescribing information, the Summary of Product Characteristics, and the information for vaccine recipients, the Patient Information Leaflet. A recognised, very rare risk of Stamaril vaccine is Yellow Fever Vaccine-Associated Neurotropic Disease, known as YEL-AND. Whilst the symptoms of YEL-AND can include confusion and acute focal neurological deficits (e.g. affecting motor co-ordination), this is not typically associated with psychosis or other long-term psychiatric disorders.</p><p> </p><p>Further to other recent reports of serious suspected adverse reactions in United Kingdom travellers, the MHRA is in the process of further reviewing the balance of benefits and risks of Yellow Fever vaccine, which will include an analysis of neuropsychiatric events.</p> answering member constituency Thurrock answering member printed Jackie Doyle-Price grouped question UIN 216210 216213 question first answered 12/02/2019 17:04:11 answering member 4065 label Biography information for Dame Jackie Doyle-Price
tabling member	1522 label Biography information for Adam Holloway

1054829

registered interest
date	04/02/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Yellow Fever: Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, if he will commission research into new vaccines for yellow fever in the event that Sanofi Pasteur does not undertake research into its yellow fever vaccine.
tabling member constituency	Gravesham
tabling member printed	Adam Holloway
uin	216212
answer	answer is ministerial correction date of answer 12/02/2019 answer text <p>The Department’s National Institute for Health Research (NIHR) welcomes funding applications for research into any aspect of human health, including the development of cheaper vaccines. These applications are subject to peer review and judged in open competition, with awards being made on the basis of the importance of the topic to patients and health and care services, value for money and scientific quality. In all disease areas, the amount of NIHR funding depends on the volume and quality of scientific activity.</p><p> </p><p>The NIHR and the Medical Research Council both have a wide portfolio of research activity in vaccines which cover clinical trials for new vaccines, new technologies, ways of improving uptake and cost effectiveness.</p> answering member constituency Gosport answering member printed Caroline Dinenage question first answered 12/02/2019 16:24:27 answering member 4008 label Biography information for Dame Caroline Dinenage
tabling member	1522 label Biography information for Adam Holloway

1054830

registered interest
date	04/02/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Yellow Fever: Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, if he will make an assessment of the potential merits of including psychosis in the list of potential side effects published on the use of Stamaril as a vaccine for yellow fever.
tabling member constituency	Gravesham
tabling member printed	Adam Holloway
uin	216213
answer	answer is ministerial correction date of answer 12/02/2019 answer text <p>As with all vaccines and medicines, the Medicines and Healthcare products Regulatory Agency (MHRA) closely monitors the safety of Stamaril yellow fever vaccine. The MHRA takes advice from the Government's independent scientific advisory body, the Commission on Human Medicines, when evaluating the risks and benefits of medicines and vaccines.</p><p> </p><p>The Marketing Authorisation Holder for Stamaril, Sanofi Pasteur, has statutory obligations to continuously monitor the safety, and balance of benefits and risks, of the vaccine.</p><p> </p><p>The potential risks of Stamaril are described in the prescribing information, the Summary of Product Characteristics, and the information for vaccine recipients, the Patient Information Leaflet. A recognised, very rare risk of Stamaril vaccine is Yellow Fever Vaccine-Associated Neurotropic Disease, known as YEL-AND. Whilst the symptoms of YEL-AND can include confusion and acute focal neurological deficits (e.g. affecting motor co-ordination), this is not typically associated with psychosis or other long-term psychiatric disorders.</p><p> </p><p>Further to other recent reports of serious suspected adverse reactions in United Kingdom travellers, the MHRA is in the process of further reviewing the balance of benefits and risks of Yellow Fever vaccine, which will include an analysis of neuropsychiatric events.</p> answering member constituency Thurrock answering member printed Jackie Doyle-Price grouped question UIN 216210 216211 question first answered 12/02/2019 17:04:11 answering member 4065 label Biography information for Dame Jackie Doyle-Price
tabling member	1522 label Biography information for Adam Holloway

1054831

registered interest
date	04/02/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Yellow Fever: Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, if he will make an assessment of the potential merits on including yellow fever in the list of vaccines under the Vaccine Damage Payment Act 1979 for which compensation may be paid.
tabling member constituency	Gravesham
tabling member printed	Adam Holloway
uin	216214
answer	answer is ministerial correction date of answer 12/02/2019 answer text <p>The Vaccine Damage Payment Scheme (VDPS) is not a compensation scheme. There is no assessment of what losses were actually suffered. It provides a one off tax-free lump sum payment, currently £120,000, to successful claimants and is one part of the wide range of support and help available to severely disabled people in the United Kingdom.</p><p> </p><p>The VDPS is primarily designed to cover adverse reactions for vaccination in the child immunisation programme which is a Government initiative to protect the community from infectious disease and does not include travel vaccines.</p><p> </p><p>The Scheme is being kept under review if further inclusions are thought necessary.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 12/02/2019 11:47:07 answering member 4067 label Biography information for Steve Brine
tabling member	1522 label Biography information for Adam Holloway